menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Emerging New Therapies for Multiple Sclerosis Patients

close
Emerging New Therapies for Multiple Sclerosis Patients
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    For years, patients with multiple sclerosis have had to rely on injectable medications. But several new oral medications are emerging, and one drug has already been approved by the FDA. Why has it taken so long to develop oral formulations? Dr. Jeffrey Cohen, director of the Millen Experimental Therapeutics program at the Cleveland Clinic and professor of medicine at the Cleveland Clinic Lerner College of Medicine, joins host Dr. Anthony Alessi to discuss how these new drugs work, the side effects, and which patients can most benefit from new oral therapy.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    For years, patients with multiple sclerosis have had to rely on injectable medications. But several new oral medications are emerging, and one drug has already been approved by the FDA. Why has it taken so long to develop oral formulations? Dr. Jeffrey Cohen, director of the Millen Experimental Therapeutics program at the Cleveland Clinic and professor of medicine at the Cleveland Clinic Lerner College of Medicine, joins host Dr. Anthony Alessi to discuss how these new drugs work, the side effects, and which patients can most benefit from new oral therapy.

Facebook Comments

Programs 7/24/21